Compare GOSS & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | AMTX |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 98.6M |
| IPO Year | 2018 | 2023 |
| Metric | GOSS | AMTX |
|---|---|---|
| Price | $0.34 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $4.19 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 10.5M | 2.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.98 |
| EPS | ★ N/A | N/A |
| Revenue | $48,471,000.00 | ★ $77,194,000.00 |
| Revenue This Year | N/A | $68.03 |
| Revenue Next Year | $144.43 | $50.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 174.60 |
| 52 Week Low | $0.32 | $1.22 |
| 52 Week High | $3.87 | $3.66 |
| Indicator | GOSS | AMTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 56.22 |
| Support Level | $0.33 | $2.73 |
| Resistance Level | $0.60 | $2.84 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 13.87 | 24.07 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.